Novo Nordisk A/S

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2022, 2021, 2020, 2019, 2018, 2016, 2015

In its 2023 reporting, Novo Nordisk A/S disclosed greenhouse gas emissions of 3.8M tonnes CO2e/year (Scope 1 2 & 3). By scope: Scope 1: 78.0K tonnes CO2e/year; Scope 2: 15.0K tonnes CO2e/year; Scope 3: 3.7M tonnes CO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
3.8M tonnes CO2e/year (Scope 1 2 & 3)
2023
⚡
Renewable Energy
100% of total energy use at production sites
of total energy
💧
Water Usage
4.2M m3/year
2023
♻️
Waste
189.1K tons/year
2023
⚙️
Energy Use
3.8M GJ/year
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).78.0K tonnes CO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.15.0K tonnes CO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).3.7M tonnes CO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
20233.8M tonnes CO2e/year (Scope 1 2 & 3)
20222.1M tCO2e/year (Scope 1 2 and 3)
2021174.0K tonnes of CO2
2020170.0K tonnes CO2e
2018127.0K tons CO2e/year (production sites and distribution)

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Reduce water consumption by 10% by 2025 (implied)
  • Collect 25% of injection pens in Denmark within the industry pilot’s first year, and achieve an 85% recycling rate by the end of 2024

📅 Medium-term

  • Achieve zero CO2e emissions from operations and transportation by 2030
  • Reach 100,000 vulnerable children and young people living with type 1 diabetes by 2030
  • Achieve a balanced gender representation across all managerial levels and a minimum of 45% women and 45% men in senior leadership positions by the end of 2025

🌱 ESG Focus Areas

Climate changePatient protection and quality of lifeBusiness conductResource use and circular economyWorkers' wellbeingBiodiversity and ecosystemsWater and marine resourcesSustainable taxPollutionAffected communitiesBioethics

⚠️ Challenges & Risks +

  • Supply chain pressure resulting in periodic constraints across product portfolio due to surging demand
  • Growing burden of chronic diseases on healthcare systems
  • Minimising the use of plastic derived from fossil fuels in medical injection devices
  • Improving affordability and access to care for vulnerable patients globally
  • Addressing the obesity pandemic holistically

📋 Report Information

Reporting Period: 2023
Frameworks: GRI, VRF, TCFD, UNGC, CDP, EU Taxonomy
Assurance: Deloitte Statsautoriseret Revisionspartnerselskab